Skip to main content
Erschienen in: Cellular Oncology 2/2017

04.01.2017 | Original Paper

microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression

Erschienen in: Cellular Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite advances that have been made in systemic chemotherapy, the prognosis of advanced triple-negative breast cancer (TNBC) patients is still poor. The identification of key factors governing TNBC development is considered imperative for the development of novel effective therapeutic approaches. Previously, it has been reported that microRNA (miR)-761 may act as either a tumor suppressor or as an oncogene in different types of cancer. Here, we aimed at assessing the biological role of this miRNA in TNBC.

Methods

First, we measured the expression of miR-761 in primary breast cancer tissues and breast cancer-derived cell lines using qRT-PCR. Subsequently, over-expression and silencing experiments were performed to determine the role of miR-761 in TNBC cell proliferation, colony formation, migration and invasion in vitro. The in vivo role of miR-761 in TNBC growth and metastasis was determined in mouse models. Bioinformatics analyses, dual-luciferase reporter assays, Western blot analyses and rescue experiments were performed to identify miR-761 target gene(s).

Results

We found that miR-761 was up-regulated in primary breast cancer tissues and its derived cell lines and, particularly, in TNBC tissues and cell lines. We also found that exogenous miR-761 over-expression augmented in vitro TNBC cell proliferation, colony formation, migration and invasion, whereas miR-761 down-regulation impaired these features. In vivo, we found that miR-761 over-expression facilitated TNBC growth and lung metastasis. Mechanistically, miR-761 was found to negatively regulate the expression of tripartite motif-containing 29 (TRIM29) in TNBC cells by binding to the 3′-untranslated region of its mRNA. In conformity with these results, a significant negative correlation between miR-761 expression and TRIM29 protein expression was noted in primary TNBC tissues (r = −0.452, p = 0.0126). We also found that exogenous TRIM29 over-expression reversed the proliferative and invasive capacities of TNBC cells.

Conclusions

Our data indicate that miR-761 acts as an oncogene in TNBC. This mode of action can, at least partially, be ascribed to the down-regulation of its target TRIM29. We suggest that miR-761 may serve as a promising therapeutic target for TNBC.
Literatur
1.
Zurück zum Zitat L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015)CrossRefPubMed L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015)CrossRefPubMed
2.
Zurück zum Zitat G. Palma, G. Frasci, A. Chirico, E. Esposito, C. Siani, C. Saturnino, C. Arra, G. Ciliberto, A. Giordano, M. D’Aiuto, Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 6, 26560–26574 (2015)CrossRefPubMedPubMedCentral G. Palma, G. Frasci, A. Chirico, E. Esposito, C. Siani, C. Saturnino, C. Arra, G. Ciliberto, A. Giordano, M. D’Aiuto, Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 6, 26560–26574 (2015)CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat I. Fkih M’hamed, M. Privat, F. Ponelle, F. Penault-Llorca, A. Kenani, Y.J. Bignon, Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers. Cell. Oncol. 38, 433–442 (2015)CrossRef I. Fkih M’hamed, M. Privat, F. Ponelle, F. Penault-Llorca, A. Kenani, Y.J. Bignon, Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers. Cell. Oncol. 38, 433–442 (2015)CrossRef
4.
Zurück zum Zitat C.B. Moelans, E.J. Vlug, C. Ercan, P. Bult, H. Buerger, G. Cserni, P.J. van Diest, P.W. Derksen, Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cell. Oncol. 38, 397–405 (2015)CrossRef C.B. Moelans, E.J. Vlug, C. Ercan, P. Bult, H. Buerger, G. Cserni, P.J. van Diest, P.W. Derksen, Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cell. Oncol. 38, 397–405 (2015)CrossRef
5.
Zurück zum Zitat E. Robles-Escajeda, U. Das, N.M. Ortega, K. Parra, G. Francia, J.R. Dimmock, A. Varela-Ramirez, R.J. Aguilera, A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell. Oncol. 39, 265–277 (2016)CrossRef E. Robles-Escajeda, U. Das, N.M. Ortega, K. Parra, G. Francia, J.R. Dimmock, A. Varela-Ramirez, R.J. Aguilera, A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell. Oncol. 39, 265–277 (2016)CrossRef
6.
Zurück zum Zitat J. Hugh, J. Hanson, M.C. Cheang, T.O. Nielsen, C.M. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, E. Magherini, J. Mackey, M. Martin, C. Vogel, Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 27, 1168–1176 (2009)CrossRefPubMedPubMedCentral J. Hugh, J. Hanson, M.C. Cheang, T.O. Nielsen, C.M. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, E. Magherini, J. Mackey, M. Martin, C. Vogel, Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 27, 1168–1176 (2009)CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat J. Collignon, L. Lousberg, H. Schroeder, G. Jerusalem, Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer 8, 93–107 (2016)PubMedPubMedCentral J. Collignon, L. Lousberg, H. Schroeder, G. Jerusalem, Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer 8, 93–107 (2016)PubMedPubMedCentral
8.
Zurück zum Zitat Q. Huang, B. Xiao, X. Ma, M. Qu, Y. Li, P. Nagarkatti, M. Nagarkatti, J. Zhou, MicroRNAs associated with the pathogenesis of multiple sclerosis. J. Neuroimmunol. 295-296, 148–161 (2016)CrossRefPubMed Q. Huang, B. Xiao, X. Ma, M. Qu, Y. Li, P. Nagarkatti, M. Nagarkatti, J. Zhou, MicroRNAs associated with the pathogenesis of multiple sclerosis. J. Neuroimmunol. 295-296, 148–161 (2016)CrossRefPubMed
9.
Zurück zum Zitat M. Tomasetti, M. Amati, L. Santarelli, J. Neuzil, microRNA in metabolic re-programming and their role in tumorigenesis. Int. J. Mol. Sci. 17, 754 (2016) M. Tomasetti, M. Amati, L. Santarelli, J. Neuzil, microRNA in metabolic re-programming and their role in tumorigenesis. Int. J. Mol. Sci. 17, 754 (2016)
10.
Zurück zum Zitat V. Taucher, H. Mangge, J. Haybaeck, Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application. Cell. Oncol. 39, 295–318 (2016)CrossRef V. Taucher, H. Mangge, J. Haybaeck, Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application. Cell. Oncol. 39, 295–318 (2016)CrossRef
11.
Zurück zum Zitat A. Ferraro, Altered primary chromatin structures and their implications in cancer development. Cell. Oncol. 39, 195–210 (2016)CrossRef A. Ferraro, Altered primary chromatin structures and their implications in cancer development. Cell. Oncol. 39, 195–210 (2016)CrossRef
12.
Zurück zum Zitat E. Tsouko, J. Wang, D.E. Frigo, E. Aydoğdu, C. Williams, miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis 36, 1051–1060 (2015)CrossRefPubMed E. Tsouko, J. Wang, D.E. Frigo, E. Aydoğdu, C. Williams, miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis 36, 1051–1060 (2015)CrossRefPubMed
13.
Zurück zum Zitat X. Sui, X. Wang, W. Han, D. Li, Y. Xu, F. Lou, J. Zhou, X. Gu, J. Zhu, C. Zhang, H. Pan, MicroRNAs-mediated cell fate in triple negative breast cancers. Cancer Lett. 361, 8–12 (2015)CrossRefPubMed X. Sui, X. Wang, W. Han, D. Li, Y. Xu, F. Lou, J. Zhou, X. Gu, J. Zhu, C. Zhang, H. Pan, MicroRNAs-mediated cell fate in triple negative breast cancers. Cancer Lett. 361, 8–12 (2015)CrossRefPubMed
14.
Zurück zum Zitat A. Yan, C. Yang, Z. Chen, C. Li, L. Cai, MiR-761 promotes progression and metastasis of non-small cell lung cancer by targeting ING4 and TIMP2. Cell. Physiol. Biochem. 37, 55–66 (2015)CrossRefPubMed A. Yan, C. Yang, Z. Chen, C. Li, L. Cai, MiR-761 promotes progression and metastasis of non-small cell lung cancer by targeting ING4 and TIMP2. Cell. Physiol. Biochem. 37, 55–66 (2015)CrossRefPubMed
15.
Zurück zum Zitat C. Shi, Z. Zhang, miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma. Tumour Biol. 37, 5437–5443 (2016)CrossRefPubMed C. Shi, Z. Zhang, miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma. Tumour Biol. 37, 5437–5443 (2016)CrossRefPubMed
16.
Zurück zum Zitat X. Zhou, L. Zhang, B. Zheng, Y. Yan, Y. Zhang, H. Xie, L. Zhou, S. Zheng, W. Wang, MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting mitofusin-2. Cancer Sci. 107, 424–432 (2016)CrossRefPubMedPubMedCentral X. Zhou, L. Zhang, B. Zheng, Y. Yan, Y. Zhang, H. Xie, L. Zhou, S. Zheng, W. Wang, MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting mitofusin-2. Cancer Sci. 107, 424–432 (2016)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) method. Methods 25, 402–408 (2001)CrossRefPubMed K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) method. Methods 25, 402–408 (2001)CrossRefPubMed
18.
Zurück zum Zitat L. Ai, W.J. Kim, M. Alpay, M. Tang, C.E. Pardo, S. Hatakeyama, W.S. May, M.P. Kladde, C.D. Heldermon, E.M. Siegel, K.D. Brown, TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res. 74, 4875–4887 (2014)CrossRefPubMedPubMedCentral L. Ai, W.J. Kim, M. Alpay, M. Tang, C.E. Pardo, S. Hatakeyama, W.S. May, M.P. Kladde, C.D. Heldermon, E.M. Siegel, K.D. Brown, TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res. 74, 4875–4887 (2014)CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat J. Liu, B. Welm, K.M. Boucher, M.T. Ebbert, P.S. Bernard, TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer. Am. J. Pathol. 180, 839–847 (2012)CrossRefPubMed J. Liu, B. Welm, K.M. Boucher, M.T. Ebbert, P.S. Bernard, TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer. Am. J. Pathol. 180, 839–847 (2012)CrossRefPubMed
20.
Zurück zum Zitat P. Krishnan, S. Ghosh, B. Wang, D. Li, A. Narasimhan, R. Berendt, K. Graham, J.R. Mackey, O. Kovalchuk, S. Damaraju, Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics 16, 735 (2015)CrossRefPubMedPubMedCentral P. Krishnan, S. Ghosh, B. Wang, D. Li, A. Narasimhan, R. Berendt, K. Graham, J.R. Mackey, O. Kovalchuk, S. Damaraju, Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics 16, 735 (2015)CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat E. van Schooneveld, H. Wildiers, I. Vergote, P.B. Vermeulen, L.Y. Dirix, S.J. Van Laere, Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 17, 21 (2015)CrossRefPubMedPubMedCentral E. van Schooneveld, H. Wildiers, I. Vergote, P.B. Vermeulen, L.Y. Dirix, S.J. Van Laere, Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 17, 21 (2015)CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat R. Maqbool, R. Rashid, R. Ismail, S. Niaz, N.A. Chowdri, M.U. Hussain, The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers. Cell. Oncol. 38, 443–451 (2015)CrossRef R. Maqbool, R. Rashid, R. Ismail, S. Niaz, N.A. Chowdri, M.U. Hussain, The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers. Cell. Oncol. 38, 443–451 (2015)CrossRef
23.
Zurück zum Zitat L. Ma, Y. Liu, C. Geng, X. Qi, J. Jiang, Estrogen receptor β inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2. Int. J. Oncol. 42, 1993–2000 (2013)PubMed L. Ma, Y. Liu, C. Geng, X. Qi, J. Jiang, Estrogen receptor β inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2. Int. J. Oncol. 42, 1993–2000 (2013)PubMed
24.
Zurück zum Zitat L. Wang, D.G. Heidt, C.J. Lee, H. Yang, C.D. Logsdon, L. Zhang, E.R. Fearon, M. Ljungman, D.M. Simeone, Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 15, 207–219 (2009)CrossRefPubMedPubMedCentral L. Wang, D.G. Heidt, C.J. Lee, H. Yang, C.D. Logsdon, L. Zhang, E.R. Fearon, M. Ljungman, D.M. Simeone, Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 15, 207–219 (2009)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat X.M. Zhou, R. Sun, D.H. Luo, J. Sun, M.Y. Zhang, M.H. Wang, Y. Yang, H.Y. Wang, S.J. Mai, Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget 7, 13634–13650 (2016)PubMedPubMedCentral X.M. Zhou, R. Sun, D.H. Luo, J. Sun, M.Y. Zhang, M.H. Wang, Y. Yang, H.Y. Wang, S.J. Mai, Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget 7, 13634–13650 (2016)PubMedPubMedCentral
26.
Zurück zum Zitat F. Qiu, J.P. Xiong, J. Deng, X.J. Xiang, TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int. J. Clin. Exp. Pathol. 8, 5053–5061 (2015)PubMedPubMedCentral F. Qiu, J.P. Xiong, J. Deng, X.J. Xiang, TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int. J. Clin. Exp. Pathol. 8, 5053–5061 (2015)PubMedPubMedCentral
27.
Zurück zum Zitat P.L. Palmbos, L. Wang, H. Yang, Y. Wang, J. Leflein, M.L. Ahmet, J.E. Wilkinson, C. Kumar-Sinha, G.M. Ney, S.A. Tomlins, S. Daignault, L.P. Kunju, X.R. Wu, Y. Lotan, M.E. Liebert, M.E. Ljungman, D.M. Simeone, ATDC/TRIM29 drives invasive bladder cancer formation through miRNA-mediated and epigenetic mechanisms. Cancer Res. 75, 5155–5166 (2015)CrossRefPubMedPubMedCentral P.L. Palmbos, L. Wang, H. Yang, Y. Wang, J. Leflein, M.L. Ahmet, J.E. Wilkinson, C. Kumar-Sinha, G.M. Ney, S.A. Tomlins, S. Daignault, L.P. Kunju, X.R. Wu, Y. Lotan, M.E. Liebert, M.E. Ljungman, D.M. Simeone, ATDC/TRIM29 drives invasive bladder cancer formation through miRNA-mediated and epigenetic mechanisms. Cancer Res. 75, 5155–5166 (2015)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat M.R. Clarke, F.M. Imhoff, S.K. Baird, Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and -2. Mol. Carcinog. 54, 1214–1219 (2015)CrossRefPubMed M.R. Clarke, F.M. Imhoff, S.K. Baird, Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and -2. Mol. Carcinog. 54, 1214–1219 (2015)CrossRefPubMed
29.
Zurück zum Zitat Z. Li, Y. Xie, W. Sheng, J. Miao, J. Xiang, J. Yang, Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo. Cancer Biother. Radiopharm. 25, 427–437 (2010)CrossRefPubMed Z. Li, Y. Xie, W. Sheng, J. Miao, J. Xiang, J. Yang, Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo. Cancer Biother. Radiopharm. 25, 427–437 (2010)CrossRefPubMed
Metadaten
Titel
microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression
Publikationsdatum
04.01.2017
Erschienen in
Cellular Oncology / Ausgabe 2/2017
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0312-6

Weitere Artikel der Ausgabe 2/2017

Cellular Oncology 2/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …